Our new website is coming soon, give it a try now and let us have your feedback. Take me to the Beta



Register
Login:
Share:
Email Facebook Twitter

TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake Watch Now

TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake
Exclusive: Hardman & Co Investor Forum - Severn Trent, Calculus Capital, Volta Finance, Residential


Glaxosmithkline Share News (GSK)

Stock Market news at lse.co.uk - RSS News Feeds

Share News for Glaxosmithkline (GSK)


Share Price: 1,584.40Bid: 1,587.00Ask: 1,587.20Change: 0.00 (0.00%)No Movement on Glaxosmithkline
Spread: 0.20Spread as %: 0.01%Open: 1,567.00High: 0.00Low: 0.00Yesterday’s Close: 1,584.40




UPDATE 4-GSK sees shingles vaccine sales rising, as free cash flow concerns weigh

Wed, 1st May 2019 12:29

(Adds details on respiratory drugs performance)

* Vaccines unit sales surge 20 percent, led by Shingrix

* Shingrix sales to be "significantly" more than 1 bln stg

* Respiratory drug sales below forecasts, weigh on shares

By Ankur Banerjee and Pushkala Aripaka

May 1 (Reuters) - GlaxoSmithKline forecast on Wednesday that 2019 sales of its shingles vaccine would be more than 1 billion pounds ($1.3 billion) but the British drugmaker's shares slipped on concerns about its pharmaceutical business and free cash flow.

Shingrix, the shingles vaccine launched in 2017, is an important source of growth for Chief Executive Emma Walmsley, as she strives to improve GSK's commercial performance after streamlining its operations and spinning off or selling units.

"Shingrix has delivered another fantastic performance in the quarter," Walmsley said on a media call.

The company said it expected sales of the vaccine to be "significantly" more than 1 billion pounds in 2019.

The strength in its vaccines unit, whose sales rose 20 percent in the quarter to the end of March, comes at a time when some of GSK's major drugs face generic competition.

Walmsley, who took over as CEO of GSK in 2017, has been looking to re-energise the drugmaker's pharmaceutical business, its biggest unit, buying U.S. cancer specialist Tesaro for $5.1 billion and giving it a presence in the oncology market.

"They are really refocusing into oncology and that's going to take some time - to make that transition - so I think its going to be a difficult time for the pharma business," said John Rountree, a partner at Novasecta Ltd, a biopharma consulting firm, adding that the vaccine business is growing.

GSK shares closed down 0.9 percent at 1,559.8 pence on Wednesday, with traders pointing to the company's respiratory drug sales, which came in at 631 million pounds, below analysts estimate of 651 million pounds.

Also, weighing on the stock was a 50 percent drop in free cash flow to 165 million pounds in the quarter, partly due to the impact of generic competition for its asthma treatment, Advair.

"GSK has again struggled to turn profits into cash," said Nicholas Hyett, equity analyst at Hargreaves Lansdown.

Net debt at GSK, which reiterated its 2019 forecast of a decline in adjusted earnings of 5 to 9 percent, hit 27.1 billion pounds at the end of the quarter from 21.6 billion pounds at the end of 2018, as the drugmaker completed its purchase of Tesaro.

"Investors should probably give GSK the benefit of the doubt, at least for now," Hyett said.

Sales of Shingrix, which prevents shingles, a viral infection of the skin that causes painful rashes, were 357 million pounds in the three-month period, up 61.5 percent from the fourth quarter.

Analysts had expected quarterly sales of 249 million pounds and are forecasting 2019 sales of 1.17 billion pounds.

Shingrix sales were largely driven by the United States, which benefited from market growth in new patient populations covered by immunisation recommendations as well as growth in Canada and the drug's recent launch in Germany. (For an interactive graphic on Shingrix sales, click here https://fingfx.thomsonreuters.com/gfx/editorcharts/GSK-RESULTS/0H001PBSW63Q/index.html)

But sales of Advair fell 15 percent to 486 million pounds, due to competition from a generic version.

GSK's turnover rose to 7.66 billion pounds in the quarter, from 7.22 billion pounds a year earlier, and above a company-provided consensus https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus of analysts' forecasts of 7.56 billion pounds.

Adjusted operating profit was 30.1 pence per share in the quarter, versus expectations of 26.1 pence per share.

($1 = 0.7653 pounds)

(Reporting by Pushkala Aripaka, Noor Zainab Hussain and Ankur Banerjee in Bengaluru Editing by Alexander Smith and Edmund Blair)



(c) Copyright Thomson Reuters 2019. Click For Restrictions - https://agency.reuters.com/en/copyright.html


Related Shares:





Germany's Stada buys six of GSK's consumer brands, eyes further deals

FRANKFURT, June 7 (Reuters) - Private equity-backed generic drugmaker Stada said on Friday it would buy six consumer healthcare products from British
[7 Jun '19 09:01]

Trump strikes "supportive" tone in meeting with British business leaders -sources

By Lawrence White and Siddharth CavaleLONDON, June 4 (Reuters) - U.S. President Donald Trump struck a positive, conciliatory tone with top British and
[4 Jun '19 15:09]

UK cross-border M&A activity slumps in early 2019

LONDON, June 4 (Reuters) - The value of cross-border company takeovers in Britain fell sharply in the first three months of 2019 as the number of acqu
[4 Jun '19 09:36]

UPDATE 2-FTSE 100 higher as trade respite lifts banks, miners

* FTSE 100 up 0.4%, FTSE 250 up 0.7%* Banks, miners top boosts* Hargreaves Lansdown down after fund suspended* Retailers hit after consumer spending s
[4 Jun '19 09:26]

GSK's Nucala wins European panel thumbs-up for self-administration

June 4 (Reuters) - GlaxoSmithKline said on Tuesday it had won marketing approval from a European Medicines Agency (EMA) panel for its Nucala drug to b
[4 Jun '19 08:20]

Let's deepen economic ties, Britain's May tells Trump

LONDON, June 3 (Reuters) - British Prime Minister Theresa May will call on U.S. President Donald Trump to deepen transatlantic economic cooperation on
[3 Jun '19 22:30]

UPDATE 2-Pharma stocks aid turnaround in FTSE 100; profit alert sinks Kier

* FTSE 100 up 0.3%* FTSE 250 down 0.5%* Pharma, consumers biggest boosts to main index* Kier at 2 decade low after profit alert (Adds company news ite
[3 Jun '19 09:12]

UPDATE 1-Lynparza stalls pancreatic cancer in patients with BRCA mutations -study

(Adds comments from AstraZeneca executive, PIX available)By Julie SteenhuysenCHICAGO, June 2 (Reuters) - AstraZeneca and Merck & Co's Lynparza helped
[2 Jun '19 18:10]



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.